🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHeart rate increase on GLP-1 — need advice Page 3

Heart rate increase on GLP-1 — need advice

wei_SG Tue, Nov 4, 2025 at 6:28 AM 13 replies 1,139 viewsPage 3 of 3
RegAffairsDC
Member
678
3,456
May 2024
Washington, DC
Nov 4, 2025 at 10:55 PM#11
Dr.LipidDallas said:
Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Printing the relevant bit and taking it with me.

Last edited: Nov 5, 2025 at 12:55 AM
30 5amy_econ_NJ, bbq_ray_KC, oliver_london and 27 others
Reply Quote Save Share Report
chris_chi24
Member
389
1,678
Sep 2024
Chicago, IL
Nov 5, 2025 at 1:01 AM#12

From the other side of the consultation, briefly.

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.

References:
[1] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.
29 4MounjBrad, nick_newbie, DadBodDave and 26 others
Reply Quote Save Share Report
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
Nov 5, 2025 at 3:07 AM#13
KevinCompounds said:
Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 →…
KevinCompounds said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

28 3Admin, Dr.Martinez, mike_mod and 25 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Nov 5, 2025 at 5:13 AM#14
wei_SG said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.

Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.

27 2emily_PDX, Dr.SleepRoch, laura_annarbor and 24 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Nov 5, 2025 at 7:19 AM#15

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source. Carry on.

Last edited: Nov 5, 2025 at 9:19 AM
26 1PurityPaulOR, MaxMetOK, MounjBrad and 23 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register